![Pierre Fabre va commercialiser et distribuer la première immunothérapie allogénique à lymphocytes T en Europe suite au transfert de l'autorisation de mise sur le marché accordée par la Commission européenne pour EBVALLO® ( Pierre Fabre va commercialiser et distribuer la première immunothérapie allogénique à lymphocytes T en Europe suite au transfert de l'autorisation de mise sur le marché accordée par la Commission européenne pour EBVALLO® (](https://mma.prnewswire.com/media/1970795/Pierre_Fabre_Atara_Logo.jpg?p=facebook)
Pierre Fabre va commercialiser et distribuer la première immunothérapie allogénique à lymphocytes T en Europe suite au transfert de l'autorisation de mise sur le marché accordée par la Commission européenne pour EBVALLO® (
![Atara Biotherapeutics et Pierre Fabre se lancent dans un partenariat stratégique pour commercialiser le tabelecleucel | MyPharma Editions Atara Biotherapeutics et Pierre Fabre se lancent dans un partenariat stratégique pour commercialiser le tabelecleucel | MyPharma Editions](https://www.mypharma-editions.com/wordpress/wp-content/uploads/2021/10/2021-10-04_152405.jpg)
Atara Biotherapeutics et Pierre Fabre se lancent dans un partenariat stratégique pour commercialiser le tabelecleucel | MyPharma Editions
![Atara Biotherapeutics announces closing of expanded global Tab Cel partnership with Pierre Fabre Labs - Medical Update Online Atara Biotherapeutics announces closing of expanded global Tab Cel partnership with Pierre Fabre Labs - Medical Update Online](https://medicalupdateonline.com/wp-content/uploads/2023/12/AdobeStock_366674524_Editorial_Use_Only.jpg)
Atara Biotherapeutics announces closing of expanded global Tab Cel partnership with Pierre Fabre Labs - Medical Update Online
![Fenwick on X: "Congrats to Atara Biotherapeutics, Inc (Nasdaq: ATRA) in its expanded partnership with Pierre Fabre Laboratories for the U.S. & remaining global commercial markets for tab-cel for up to $640 Fenwick on X: "Congrats to Atara Biotherapeutics, Inc (Nasdaq: ATRA) in its expanded partnership with Pierre Fabre Laboratories for the U.S. & remaining global commercial markets for tab-cel for up to $640](https://pbs.twimg.com/tweet_video_thumb/F94GNuZWMAAxIDC.jpg)
Fenwick on X: "Congrats to Atara Biotherapeutics, Inc (Nasdaq: ATRA) in its expanded partnership with Pierre Fabre Laboratories for the U.S. & remaining global commercial markets for tab-cel for up to $640
![EMA to review Atara's MAA submission for allogeneic T-cell therapy: 'A watershed moment for the field' EMA to review Atara's MAA submission for allogeneic T-cell therapy: 'A watershed moment for the field'](https://www.biopharma-reporter.com/var/wrbm_gb_food_pharma/storage/images/_aliases/wrbm_large/publications/pharmaceutical-science/biopharma-reporter.com/article/2021/11/30/ema-to-review-atara-s-maa-submission-for-allogeneic-t-cell-therapy-a-watershed-moment-for-the-field/13052871-1-eng-GB/EMA-to-review-Atara-s-MAA-submission-for-allogeneic-T-cell-therapy-A-watershed-moment-for-the-field.jpg)
EMA to review Atara's MAA submission for allogeneic T-cell therapy: 'A watershed moment for the field'
![Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results | Business Wire Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results | Business Wire](https://mms.businesswire.com/media/20231031702630/en/792504/22/Atara-Bio1_logo_300x185-1.jpg)
Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results | Business Wire
![Atara Biotherapeutics Inc.: Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress - Form 8-K - MoneyController (ID 1539617) Atara Biotherapeutics Inc.: Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress - Form 8-K - MoneyController (ID 1539617)](https://www.moneycontroller.fr/upload/aziende/atara-biotherapeutics-inc_20210427131418.png)
Atara Biotherapeutics Inc.: Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress - Form 8-K - MoneyController (ID 1539617)
![Prima immunoterapia allogenica a cellule T, la commercializzazione in Europa passa da Atara a Pierre Fabre - AboutPharma Prima immunoterapia allogenica a cellule T, la commercializzazione in Europa passa da Atara a Pierre Fabre - AboutPharma](https://www.aboutpharma.com/wp-content/uploads/2023/02/cellule-t-e1676473829469.jpg)
Prima immunoterapia allogenica a cellule T, la commercializzazione in Europa passa da Atara a Pierre Fabre - AboutPharma
![Atara Bio to get additional $30M milestone payment under collaboration with Pierre Fabre | Seeking Alpha Atara Bio to get additional $30M milestone payment under collaboration with Pierre Fabre | Seeking Alpha](https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1372108967/image_1372108967.jpg?io=getty-c-w1280)
Atara Bio to get additional $30M milestone payment under collaboration with Pierre Fabre | Seeking Alpha
![Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories | ATRA Stock News Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories | ATRA Stock News](https://static.stocktitan.net/company-logo/ATRA-lg.png)
Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories | ATRA Stock News
![Les Laboratoires Pierre Fabre accélèrent leur développement dans le domaine de l'onco-hématologie grâce à l'acquisition aux Etats-Unis d'une licence pour une immunothérapie à lymphocytes T Les Laboratoires Pierre Fabre accélèrent leur développement dans le domaine de l'onco-hématologie grâce à l'acquisition aux Etats-Unis d'une licence pour une immunothérapie à lymphocytes T](https://mma.prnewswire.com/media/1328780/Pierre_Fabre_Logo.jpg?p=facebook)